Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult male or females with prior diagnosis of Diabetic Kidney Disease
Type 2 diabetes mellitus diagnosis for at least 6 months
eGFR (MDRD) at screening ≥ 15 mL/min/1.73m\^2 to \< 60 mL/min/1.73m\^2
Urine albumin to creatinine ratio (UACR) as follows:
* Stage/Stratum 3a: eGFR range 45 to \< 60 mL/min; UACR ≥ 600 mg/g
* Stage/Stratum 3b: eGFR range 30 to \< 45 mL/min; UACR ≥ 300 mg/g
* Stage/Stratum 4: eGFR range 15 to \< 30 mL/min; UACR ≥ 150 mg/g
Receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARB) at a minimum dose deemed appropriate for the individual by the investigator and be at a stable dose for the last three months
* Individuals not on ACEi/ARB may be screened if there is documented intolerance to ACE inhibitor and/or ARB
You may not be if
Type 1 diabetes mellitus
HbA1c \> 9.5%
Non-diabetic kidney disease
UACR \> 5000 mg/g on any measurement during screening
End stage renal disease (ESRD; receiving peritoneal dialysis, hemodialysis, or status post renal transplantation) or anticipated to occur within the treatment period
Unstable cardiovascular disease
Pregnant or lactating females
Clareo Health | Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
